Drug Approval | April 26, 2022
USFDA approves first Covid-19 treatment for young children
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
The approval is for Cytomegalovirus, a type of Herpes virus
EaseVRx employs the principles of cognitive behavioural therapy and other behavioural therapy techniques for the reduction of pain and pain interference
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Subscribe To Our Newsletter & Stay Updated
